FutureLife Group
- Company typePrivate
- Founded1991
- HeadquartersPrague, Czechia
- Headcount—
- GTM typeB2C
- OfferingServices
FutureLife Group firmographics
Firmographics- Name
- FutureLife Group
- Legal name
- FutureLife a.s.
- Website
- https://futurelifegroup.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Ownership category
- akta.pro rank
FutureLife Group industry classification
Industry- Product category
- Reproductive Medicine and Fertility Services
- NAICS
- Family Planning Centers (621410)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)
- akta.pro secondary industry
- Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
Keywords
Where FutureLife Group is headquartered
LocationHeadquarters
- HQ city
- Prague
- HQ country
- Czechia
- HQ region
- Europe
Offices1 record
Markets served
FutureLife Group business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- IVF Treatment Cycles: Core revenue from fertility treatments including IVF cycles, IUI, donor programs, and fertility preservation. The company performs over 77,000 IVF cycles annually across its network.
- Genetic Testing Services: Revenue from genetic laboratory services including PGT, carrier tests, and diagnostic tests through GNTlabs by GENNET.
- Pharmacy (Serpha): Online pharmacy specializing in fertility medication, operating across Netherlands and other markets.
- Hospital and Surgical Services: Two hospitals in Czech Republic plus gynecological and surgical treatments at clinic network.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
FutureLife Group product offering
Product offeringCore offering
FutureLife Group operates a pan-European network of fertility, IVF, and genetics clinics delivering assisted reproduction services such as IVF, IUI, donor programmes, and fertility preservation. The group runs 62 clinics across 16 countries supported by an in-house genetic laboratory (GNTlabs by GENNET) and an online fertility pharmacy (Serpha). It has performed more than 77,000 IVF cycles annually and integrated a CE-marked AI platform (Embryo Predict, Success Predictor, Egg Retrieval Report) network-wide for clinical decision support.
Product overview
FutureLife Group is a pan-European fertility and reproductive medicine provider operating a multi-brand, multi-clinic platform. The core offering includes fertility treatments (IUI, IVF, donor programmes, fertility preservation) supported by the FutureLife Gamete Bank and GNTlabs genetic laboratory. The company has expanded through acquisitions of leading regional fertility brands including CRGH, Herts & Essex, BCRM, Institut Marquès, Nij Group, Nova Vita/Ovumia, BabyScan, and clinics in Romania (Gynera, Gynatal, Atentica, CytoGenomic), as well as the Bahceci Group in Turkey. Recent AI integration includes deployment of Alife Health's Embryo Predict, Success Predictor, and Egg Retrieval Report tools across the clinic network.
Differentiator
Problem solved
Functional benefit
Brands
- GNTlabs by GENNET: One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, PGT, and bioinformatics
- FutureLife Gamete Bank
- Serpha
- CRGH
- Reprofit
- GENNET
- City Fertility
Products and services
- In Vitro Fertilization (IVF) A highly effective fertility treatment where fertility hormones stimulate the ovaries to produce eggs, which are collected and combined with sperm in a laboratory to create embryos for transfer. Offered to individuals and couples experiencing infertility across FutureLife's network of 62 clinics in 16 European countries.
- Intrauterine Insemination (IUI) A fertility treatment involving placement of sperm directly inside the womb around the time of ovulation, performed in natural or medicated cycles. Less invasive than IVF and offered to patients across the FutureLife clinic network.
- Donor Programme Treatment pathway using donated eggs or sperm to help individuals and couples create families, supported by FutureLife Gamete Bank as Europe's leading donor egg bank.
- Fertility Preservation (Egg Freezing) Oocyte cryopreservation allowing women to preserve fertility by freezing and storing eggs for future use, including for medical (e.g., before cancer treatment) or social reasons. Offered across FutureLife's clinic network.
- FutureLife Gamete Bank Europe's leading donor egg bank providing best-in-class assisted reproductive technology care through thorough screening, skilled doctors, and a caring approach to maximize chances of success for patients across Europe.
- GNTlabs by GENNET One of Europe's most advanced genetic laboratories, operated as a wholly owned subsidiary of FutureLife, specializing in molecular genetics, cytogenetics, preimplantation genetic testing (PGT), bioinformatics, embryology, and immunology. Offers disease risk screenings, carrier tests, and diagnostic tests for genetic disorders.
- Serpha Online Pharmacy Online pharmacy operated as a wholly owned subsidiary of FutureLife (via Nij Group), specializing in fertility medication and serving patients across the Netherlands and other markets.
- Embryo Predict CE-marked AI tool for blastocyst evaluation and embryo assessment for transfer decisions. Uses deep learning to generate AI scores for each embryo alongside personalized patient reports. Part of Alife Health AI platform deployed across FutureLife's clinic network.
- Success Predictor Non-medical device tool providing outcome projections before fertility treatment, part of the Alife Health AI platform for patient decision support throughout the IVF journey.
- Egg Retrieval Report Tool offering patients visibility into their evolving chances of success following egg retrieval, part of the Alife Health AI platform providing patient support across the IVF journey.
- Linea Vita Genetic Test First carrier screening test developed in Romania, analyzing 150 genes responsible for 217 genetic disorders, offered through CytoGenomic Medical Laboratory in partnership with FutureLife.
Quantifiable outcome
- Over 188,795 babies delivered since 1991 (one every 36 minutes)
- +4 more outcomes
Companies that use FutureLife Group
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
FutureLife Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
FutureLife Group partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- Alife HealthcoreNetwork-wide partnership to deploy comprehensive AI platform for fertility care across all 60 clinics in 16 countries. Includes CE-marked Embryo Predict™ for blastocyst evaluation, Success Predictor™, and Egg Retrieval Report tools. FutureLife becomes the first large-scale European fertility network to adopt a multi-tool AI platform following successful multi-clinic pilot.
- Alife HealthcoreDeploys AI platform across 60+ clinics including Embryo Predict™ (CE-marked), Success Predictor™, and Egg Retrieval Report tools for comprehensive AI-assisted fertility care.
- Ethmar International Holding (EIH)majorEIH partnered with FutureLife to introduce Institut Marquès to UAE capital, paving way for regional expansion with Abu Dhabi center opening during 2026.
- Ethmar International Holding (EIH)majorStrategic partnership to bring Institut Marquès to Abu Dhabi, UAE. New center will offer IVF, fertility treatments, gynecology, holistic therapies, and wellness programs. EIH is UAE's leading progressive investment holding.
- CytoGenomic Medical LaboratorycorePartnership with Romania's leading genetic laboratory providing innovative genetic analysis and tests. CytoGenomic collaborates with 45+ clinics and hospitals, providing 15,000+ genetic analyses annually including Linea Vita carrier screening test.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
FutureLife Group competitors and assessment
Company assessmentBroad incumbents
- Virtus Health: Australia-headquartered global IVF provider with clinics across Australia, Ireland, the UK, and Singapore. Comparable as a multi-brand fertility clinic network pursuing international expansion via M&A, though it is more concentrated in the Southern Hemisphere.
- CooperCompanies (CooperSurgical): Large diversified fertility and women's health business within CooperCompanies, providing ART media, devices, and genetic testing globally. Comparable as a broad incumbent supplying — and increasingly integrating into — IVF clinical workflows.
Regional players
- Boston IVF: One of the largest US fertility clinic networks with affiliated centers across North America. Comparable as a multi-clinic fertility provider serving a similar patient base, but operating almost entirely in the US rather than Europe.
- Monash IVF Group: Australia- and Southeast Asia-focused fertility clinic network with ultrasound and genetics services. Comparable as a multi-clinic reproductive medicine platform, but primarily Asia-Pacific rather than European in footprint.
Others
- Vitrolife: Global supplier of media, consumables, and GeneSYS preimplantation genetic testing to IVF clinics. Comparable as an ecosystem enabler providing technology and lab tools that complement FutureLife's clinical operations.
- Alife Health: US-based AI platform partner for IVF clinics (Embryo Predict, Success Predictor, Egg Retrieval Report). Comparable as a strategic technology partner whose product roadmap directly shapes FutureLife's clinical AI differentiation.
Direct peers
- Genea: Global fertility company operating clinics in Australia and the UK plus a medical devices arm (Genea Biomedx). Comparable as a vertically integrated fertility network with proprietary lab technology serving a similar patient base.
- CARE Fertility: UK-based fertility clinic network offering IVF, IUI, donor programs, and genetic testing. Directly competes with FutureLife's UK brands (CRGH, BCRM, Herts & Essex) for NHS-funded and private-pay patients.
- IVI-RMA Global: World's largest assisted reproduction group, operating a network of fertility clinics across Europe, the Americas, and the Middle East. Directly comparable as a multi-country IVF clinic consolidator with full reproductive medicine, genetic, and donor services — FutureLife's clearest pan-European competitor.
- TFP Fertility: European fertility clinic group operating across the UK, Poland, the Netherlands, Denmark, and Germany. Direct competitor in the same European fertility-clinic consolidation space, focused on NHS and private-pay cycles.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
FutureLife Group social profiles
Digital presenceFutureLife Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
FutureLife Group leadership team
Management profileNumber of profiles
Profiles4 records
FutureLife Group subsidiaries and ownership
Company hierarchySubsidiaries15 records
FutureLife Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FutureLife Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FutureLife Group
What does FutureLife Group do?
FutureLife Group operates a pan-European network of fertility, IVF, and genetics clinics delivering assisted reproduction services such as IVF, IUI, donor programmes, and fertility preservation. The group runs 62 clinics across 16 countries supported by an in-house genetic laboratory (GNTlabs by GENNET) and an online fertility pharmacy (Serpha). It has performed more than 77,000 IVF cycles annually and integrated a CE-marked AI platform (Embryo Predict, Success Predictor, Egg Retrieval Report) network-wide for clinical decision support.
Is FutureLife Group a public or private company?
FutureLife Group is a private company. It is classified as private equity controlled and is currently operating.
When was FutureLife Group founded?
FutureLife Group was founded in 1991.
Where is FutureLife Group based?
FutureLife Group is headquartered in Prague, Czechia, in the Europe region.
How does FutureLife Group make money?
Four revenue lines are on record. IVF Treatment Cycles are the primary driver. The others are genetic Testing Services, pharmacy (Serpha) and hospital and Surgical Services.
Who are FutureLife Group's main competitors?
Broad incumbents on record are Virtus Health and CooperCompanies (CooperSurgical). Regional players are Boston IVF and Monash IVF Group. Others are Vitrolife and Alife Health. Direct peers are Genea, CARE Fertility, IVI-RMA Global and TFP Fertility.
Does FutureLife Group have an API?
No public API is recorded for FutureLife Group.
What industry is FutureLife Group in?
FutureLife Group's product category is Reproductive Medicine and Fertility Services. Its primary akta.pro industry code is HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers, with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 621410 and its SIC code is 8011.